JIXING Announces Leadership Transition

SHANGHAI, China, April 20, 2022 – Ji Xing Pharmaceuticals Limited (“JIXING”), a clinical-stage biopharmaceutical company committed to bringing innovative medicines to underserved Chinese patients with serious and life-threatening diseases, today announced the appointment of Peter Fong, PhD as interim Chief Executive Officer, effective June 1, 2022. Dr. Fong, who was the founding CEO of JIXING and currently serves as board executive director, will succeed Joseph Romanelli, who will be stepping down from his role as CEO.

Dr. Fong led JIXING’s formation and served as CEO for its first two years of operations, overseeing its first 45 hires, two drug in-licenses, and first clinical studies, and has remained a key advisor to the company as Board Executive Director since 2021. JIXING’s board of directors has initiated the search for a permanent CEO to lead the company’s next chapter.

“We are confident that Peter will step seamlessly back into the role of CEO alongside newly appointed Chief Commercial Officer Kun Wu and the rest of the top-notch JIXING leadership team,” said Roderick Wong, MD, JIXING’s Chairman. “We thank Joe for his contributions to JIXING and look forward to the company’s continued growth moving forward.”

“Through my experience as founding CEO and a director on JIXING’s board, I have witnessed the company’s tremendous progress and have great faith in our team’s ability to deliver on our mission,” said Dr. Fong. “I look forward to jumping back into the daily operations as we continue to advance the company’s pipeline, such as the recently announced agreement to develop and commercialize LNZ100 and LNZ101 for the treatment of presbyopia in Greater China.”